Published in Drug Week, July 28th, 2006
This randomized, controlled clinical trial builds on the promising results of earlier studies, to fully investigate the efficacy and safety of CoFactor for patients with first line metastatic colorectal cancer.
Patient eligibility screening for this pivotal trial has begun at several clinical sites. A total of 100 clinical sites in the U.S. are planned for the phase III study, following institutional review board (IRB) approval of the clinical protocol, credentialing of the investigational team and an...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.